Filing Flows › BioXcel Therapeutics (BTAIQ) › Q2 2026
BioXcel Therapeutics (BTAIQ) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
BioXcel Therapeutics (BTAIQ) reported revenue of $182K for the second quarter 2026 (Q2 2026), +52% from a year earlier and -12% from the quarter before.
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $182K | -12% | +52% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$14.7M | — | — |
| Operating cash flow | −$6.1M | — | — |
What changed
Revenue was $182K in Q2 2026, up 52% year over year and down 12% from the previous quarter.
Operating costs exceeded revenue by $10.2M, an operating margin of -5600.5%. Total costs fell 35% while revenue rose 52%. The fastest-growing cost line was SG&A (+28%). The quarter ended with a net loss of $14.7M, wider than the previous quarter's $12.7M loss.
Operating cash flow was −$6.1M. Non-cash charges added back $18K of depreciation and $358K of share-based compensation. Working capital and other items added $8.2M.
Questions
What was BioXcel Therapeutics' revenue in the second quarter 2026?
BioXcel Therapeutics (BTAIQ) reported revenue of $182K for the second quarter 2026 (Q2 2026), +52% from a year earlier and -12% from the quarter before.